Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 33: 2257-2261, 1987;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rock, R. C.
Right arrow Articles by Walsh, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rock, R. C.
Right arrow Articles by Walsh, P.

Clinical Chemistry, Vol 33, 2257-2261, Copyright © 1987 by American Association for Clinical Chemistry

Evaluation of a monoclonal immunoradiometric assay for prostate- specific antigen

RC Rock, DW Chan, D Bruzek, C Waldron, J Oesterling and P Walsh
Department of Laboratory Medicine, Johns Hopkins Hospital, Baltimore, MD 21205.

We evaluated the analytical performance of a new monoclonal immunoradiometric assay ("M-PSA") for prostate-specific antigen ("Tandem"; Hybritech Inc.) in comparison with a monoclonal immunoradiometric assay ("M-PAP") for mass measurement of prostatic acid phosphatase ("Tandem") and with a conventional enzyme-activity assay ("E-PAP") for prostatic acid phosphatase (EC 3.1.3.2). For M-PSA, the CVs were 1.3-3.0% within-run and 3.0-4.9% between-run. The minimum detectable mass concentration was 0.10 microgram/L, and linearity extended to 100 micrograms/L. The reference interval for M-PSA in 178 healthy men was 0-2.8 micrograms/L. Serum specimens from men with prostatic disease (primarily prostatic carcinoma and benign prostatic hypertrophy) were assayed by the three methods. Correlation was best between mass measurement (M-PAP) and enzyme activity (E-PAP) for prostatic acid phosphatase (r = 0.958). Results for PSA did not correlate well with those for either M-PAP (r = 0.629) or E-PAP (r = 0.387). PSA was increased in a higher percentage of specimens from men with earlier (clinical stage B) prostatic carcinoma than were results from either assay for PAP.


The following articles in journals at HighWire Press have cited this article:


Home page
 JNCI J Natl Cancer InstHome page
H. B. Carter, L. Ferrucci, A. Kettermann, P. Landis, E. J. Wright, J. I. Epstein, B. J. Trock, and E. J. Metter
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
J Natl Cancer Inst, November 1, 2006; 98(21): 1521 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. E. Oesterling, S. K. Martin, E. J. Bergstralh, and F. C. Lowe
The Use of Prostate-Specific Antigen in Staging Patients With Newly Diagnosed Prostate Cancer
JAMA, January 6, 1993; 269(1): 57 - 60.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American Association for Clinical Chemistry.